CM Management LLC Has $5.27 Million Stock Position in Amicus Therapeutics, Inc. $FOLD

Key Points

• CM Management LLC trimmed its stake in Amicus Therapeutics by 17.8% in Q4 to 370,000 shares, a position worth about $5.27 million and the fund's fourth-largest holding (0.12% of the company).
• Amicus missed quarterly EPS estimates ($0.10 vs. $0.13) while revenue rose 23.7% YoY to $185.21 million; the stock trades near its 12-month high (~$14.50) with a market cap of roughly $4.55 billion and a negative PE (~-181).
• Analysts and insiders: the consensus analyst rating is a "Hold" with an average target of $14.56, several firms have lowered ratings, and CEO Bradley L. Campbell sold 22,500 shares (insiders now own about 2.2% of the company).

CM Management LLC lessened its holdings in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 17.8% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 370,000 shares of the biopharmaceutical company's stock after selling 80,000 shares during the period. Amicus Therapeutics accounts for approximately 4.4% of CM Management LLC's holdings, making the stock its 4th biggest position. CM Management LLC owned 0.12% of Amicus Therapeutics worth $5,269,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of FOLD. Goldman Sachs Group Inc. grew its position in Amicus Therapeutics by 7.7% in the 1st quarter. Goldman Sachs Group Inc. now owns 2,703,577 shares of the biopharmaceutical company's stock worth $22,061,000 after purchasing an additional 194,213 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in Amicus Therapeutics by 11.9% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,072,474 shares of the biopharmaceutical company's stock worth $8,751,000 after purchasing an additional 113,803 shares during the last quarter. Intech Investment Management LLC grew its position in Amicus Therapeutics by 37.1% in the 1st quarter. Intech Investment Management LLC now owns 170,922 shares of the biopharmaceutical company's stock worth $1,395,000 after purchasing an additional 46,218 shares during the last quarter. Strs Ohio bought a new position in Amicus Therapeutics in the 1st quarter worth about $30,000. Finally, Cetera Investment Advisers bought a new position in Amicus Therapeutics in the 2nd quarter worth about $79,000.

Amicus Therapeutics Stock Performance

Amicus Therapeutics stock opened at $14.49 on Friday. The firm has a 50 day simple moving average of $14.42 and a 200-day simple moving average of $12.69. The company has a debt-to-equity ratio of 1.43, a current ratio of 2.84 and a quick ratio of 1.88. The stock has a market capitalization of $4.55 billion, a PE ratio of -181.13 and a beta of 0.48. Amicus Therapeutics, Inc. has a 12-month low of $5.51 and a 12-month high of $14.50.

Amicus Therapeutics (NASDAQ:FOLD - Get Free Report) last posted its quarterly earnings data on Friday, February 20th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.13 by ($0.03). The company had revenue of $185.21 million during the quarter, compared to the consensus estimate of $185.00 million. Amicus Therapeutics had a negative net margin of 4.27% and a positive return on equity of 4.15%. The company's revenue was up 23.7% on a year-over-year basis. During the same quarter last year, the business earned $0.09 earnings per share. As a group, equities research analysts expect that Amicus Therapeutics, Inc. will post 0.43 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have commented on FOLD shares. Weiss Ratings restated a "sell (d-)" rating on shares of Amicus Therapeutics in a research report on Friday, March 27th. Guggenheim cut shares of Amicus Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Monday, January 5th. Jefferies Financial Group restated a "hold" rating and issued a $14.50 target price (down from $16.00) on shares of Amicus Therapeutics in a research report on Thursday, January 22nd. Finally, Zacks Research cut shares of Amicus Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Monday, January 26th. Two analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, the stock has an average rating of "Hold" and a consensus target price of $14.56.

Insider Activity

In other news, CEO Bradley L. Campbell sold 22,500 shares of the stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $14.35, for a total value of $322,875.00. Following the completion of the transaction, the chief executive officer directly owned 998,680 shares in the company, valued at $14,331,058. This trade represents a 2.20% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 2.20% of the stock is owned by company insiders.

Amicus Therapeutics Company Profile

Amicus Therapeutics NASDAQ: FOLD is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for rare and orphan diseases. The company specializes in pharmacological chaperones and gene therapy approaches designed to address the underlying causes of lysosomal storage disorders. Its proprietary technology platform integrates structure‐based drug design with precision medicine to identify small molecules that stabilize misfolded proteins and restore cellular function.

The company's lead marketed product, Galafold (migalastat), is an oral pharmacological chaperone approved in the United States, European Union and other territories for the treatment of Fabry disease in patients with amenable genetic variants.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.